

Special Issue

Sleep-Disordered Breathing and Cardiovascular Diseases

Message from the Guest Editor

Sleep-disordered breathing (SDB) currently affects more than one billion patients worldwide. It is frequently associated with various cardiovascular disorders such as arrhythmias, systolic heart failure, diastolic dysfunction, hypertension, etc. There is an increasing perception that SDB increases cardiovascular morbidity and mortality. Therefore, further study of SDB is urgently warranted. The aim of this Special Issue is to provide new insights into SDB in the context of cardiovascular disorders. Basic scientific studies delineating pathomechanisms, as well as studies comparing different pathologies (e.g., arrhythmias or diastolic dysfunction) in patients with and without SDB, are of particular interest. Work investigating SDB in the context of cardiovascular interventions and biomarker studies (e.g., blood, ECG) are also welcome. Research in which SDB is found not to be associated with specific diseases or adverse events is also encouraged, as this will provide insights into daily practice. All types of studies and all publication formats will be considered.

Guest Editor

Dr. Simon Lebek

1. Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
2. Department of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany

Deadline for manuscript submissions

closed (30 April 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/175523

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).